The management of high-risk (HR) prostate cancer represents a challenge for radiation oncologists. This survey investigates the pattern of care in management of HR-prostate cancer across Spanish institutions.
We conducted a survey among URONCOR members from March to May 2024. This survey was structured in five sections: diagnosis, radiotherapy, hormonal treatment, follow-up, and future perspectives.
A total of 74 responses from 71 different hospitals were received. Participants have a median professional experienced of 11 years, working most of them (84.9%) in public university hospitals. 97.3% have multidisciplinary tumor board and treat a median of 50 (0-200) HR-prostate cancer patients per year/department. 44.63% of centers use Choline-PET and 28.4% PSMA-PET at diagnosis with 26 different fractionation schedules, the most common is moderate hypofractionation (52.7%): 70 Gy in 28 fractions, followed by 37.5 Gy in 15 fractions + 15 Gy brachytherapy boost (30.4%). 56.8% of the institutions perform whole-pelvic irradiation in N0 patients, with 50.4 Gy in 28 fractions (40.48%) being the most common scheme. 56.8% prescribe an LHRH agonist and 74.6% for 24 months. 75.7% prescribe abiraterone in very high-risk patients. 63.0% use the PHOENIX-criteria to define a recurrence. 38.0% perform PSMA-PET and 39.0% Choline-PET as imaging for recurrence. After local relapse, 73.97% apply a re-irradiation technique with 11 different schedules (32.35%), with HDR-brachytherapy: 13.5 Gy × 2 being the most used (56.16%). 83.8% consider that they achieved good results in HR-prostate cancer.
This study represents the current status of the management of HR-prostate cancer in Spain, highlighting the wide variety of radiotherapy treatments as well as the need for national consensus guidelines.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2025 Oct 29 [Epub ahead of print]
Victor Duque-Santana, Maria Antonia Gómez-Aparicio, Abrahams Ocanto, Elias Gomis Selles, Miren Gaztañaga, Patricia Willisch, Xavier Maldonado Pijoan, Manuel Luis Blanco-Villar, Ivan Henriquez, Pedro Carlos Lara, Ivone Ribeiro, Alai Goñi Ramirez, Marta López Valcárcel, Ignacio Visus Fernández de Manzanos, Susana Pérez Echagüen, Pilar Alonso Martínez, Victoria Vera Barragán, Carmen Velilla Millán, Ana Illescas Vacas, Pilar María Samper Ots, Luis Alberto Glaría Enríquez, Angel Montero Luis, Laura Montezuma Niño, Rocío Del Castillo Acuña, Elísabet González Del Portillo, Ferran Ferrer, Alfonso Gómez-Iturriaga, Antonio José Conde Moreno, Elia Del Cerro Peñalver, Felipe Couñago, Fernando López-Campos, URONCOR investigators
Department of Radiation Oncology, Hospital Universitario Quirónsalud Madrid, Madrid, Spain. ., Department of Radiation Oncology, Hospital Universitario Toledo, Toledo, Spain., Department of Radiation Oncology, GenesisCare, Hospital Universitario San Francisco de Asís, 28002, Madrid, Spain., Department of Radiation Oncology, Hospital Clinic Barcelona, Barcelona, Spain., Department of Radiation Oncology, GenesisCare, Hospital Universitario Clínico San Carlos Madrid, Moncloa-Aravaca, Madrid, Spain., Department of Radiation Oncology, Hospital Meixoeiro, Vigo, Spain., Department of Radiation Oncology, Hospital Universitari de La Vall d'Hebron, Barcelona, Spain., Department of Radiation Oncology, Hospital Universitario Virgen de Las Nieves, Granada, Spain., Department of Radiation Oncology, Hospital Universitario Sant Joan, Reus, Tarragona, Spain., Department of Radiation Oncology, Centro Oncológico Integral Canario, Hospital Universitario San Roque Las Palmas, Universidad Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Spain., Department of Radiation Oncology, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain., Department of Radiation Oncology, Onkologikoa - UGC Oncología Gipuzkoa, San Sebastián, Gipuzkoa, Spain., Department of Radiation Oncology, Hospital Universitario Puerta de Hierro, Madrid, Spain., Department of Radiation Oncology, Hospital Universitario de Navarra, Navarra, Spain., Department of Radiation Oncology, CIBIR-Hospital Universitario San Pedro, Logroño, La Rioja, Spain., Department of Radiation Oncology, Hospital Clínico Universitario, Valladolid, Spain., Department of Radiation Oncology, Hospital Universitario de Badajoz, Badajoz, Spain., Department of Radiation Oncology, HCU UCMORA, Zaragoza, Spain., Department of Radiation Oncology, Hospital Universitario Virgen Macarena, Seville, Spain., Department of Radiation Oncology, Hospital Universitario Rey Juan Carlos, Móstoles, Madrid, Spain., Department of Radiation Oncology, GenesisCare, Hospital Universitario La Paz, Madrid, Spain., Department of Radiation Oncology, Hospital Universitario HM Sanchinarro, Madrid, Spain., Department of Radiation Oncology, Hospital Santa Creu i Sant Pau, Horta-Guinardó, Barcelona, Spain., Department of Radiation Oncology, Hospital Universitario Punta de Europa, Algeciras, Spain., Department of Radiation Oncology, Institut Català d'Oncologia -Hospital Duran i Reynals ICO L'Hospitalet, L'Hospitalet de Llobregat, Spain., Department of Radiation Oncology, Hospital Universitario Cruces, Biobizkaia Health Research Institute, San Vicente de Barakaldo, Spain., Department of Radiation Oncology, Hospital Universitario y Politécnico La Fe, Valencia, Spain., Department of Radiation Oncology, Hospital Universitario Quirónsalud Madrid, Madrid, Spain., Department of Medicine, Faculty of Medicine, Health and Sports, European University of Madrid, Madrid, Spain., Department of Radiation Oncology, Hospital Universitario Ramon y Cajal, Madrid, Spain.
PubMed http://www.ncbi.nlm.nih.gov/pubmed/41160367